Compound ID | 3390
Class: Bacteriophage
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Active against Staphylococcus aureus and Pseudomonas aeruginosa |
| Institute where first reported: | Adaptive Phage Therapeutics |
| Year first mentioned: | 2022 |
| Highest developmental phase: | Phase 2 (NCT05269121) |
| Development status: | Terminated |
| Reason Dropped: | Withdrawn by sponsors; reason unclear |
| External links: | |
| Citation: |